News | January 07, 2015

Volcano Announces 1,000th System Activated With iFR Modality

Hybrid method avoids need for hyperemic agents that induce stress on the heart

January 7, 2015 — Volcano Corp. announced that more than 1,000 systems have been activated with its instant wave-Free Ratio (iFR) Modality software, featuring a simplified workflow and reduced need for hyperemic agents.

The iFR Modality is a physiologic measurement performed using the same pressure wires and equipment utilized in cardiac catheterization labs for fractional flow reserve (FFR) but avoids injection of hyperemic agents into the patient that induce stress to the heart. This allows for a meaningful, lesion-specific assessment in seconds by amplifying the resting pressure waveform. The iFR Modality is used most efficiently with Volcano's Verrata Pressure Guide Wire, which is designed for simple disconnection and reattachment during a procedure and facilitates multiple quick measurements without the need for hyperemic agents.

The iFR Modality and other physiologic guidance tools including FFR and coronary flow reserve (CFR) are currently being studied in numerous prospective clinical trials as part of the DEFINE family of studies. These studies are designed to explore patient outcomes in a broad array of clinical presentations in more than 5,000 patients worldwide.  The performance of the iFR Modality has been tested in approximately 800 patients as part of ADVISE II (Adenosine Vasodilator Independent Stenosis Evaluation), the first prospective, real-world registry comparing iFR and FFR. The iFR Hybrid Approach Analysis performed in the ADVISE II study demonstrated a statistically high correlation (sensitivity 90.7 percent for FFR less than or equal to 0.80, specificity 96.2 percent for FFR greater than 0.80). The hybrid method would have avoided the need to use a hyperemic agent in 65.1 percent of this patient population. Patients in ADVISE II were recruited from more than 40 centers in the United States and Europe, and all procedures were performed with operators blinded to the iFR values which were calculated offline at an independent core laboratory in Rotterdam, the Netherlands. 

"We chose to evaluate the hyperemic savings in our own subset of patients and have been very pleased with iFR," commented Vincent J. Pompili, M.D., FACC, director, Interventional Cardiovascular Medicine and Cardiac Catheterization Laboratories at The Ross Heart Hospital at The Ohio State University Wexner Medical Center. "In our subset of patients thus far, we've seen more than a 60-percent reduction in the need for hyperemic agents using the iFR Hybrid Approach, which is consistent with the ADVISE II study. Our patients appreciate not having to receive a hyperemic agent but still receive the benefits of intracoronary physiologic measurements. So far I have been impressed with the ease of use, and repeatability of the software."

For more information: www.volcanocorp.com

Related Content

An example of the Medis QCA angiography imaging derived fractional flow reserve (FFR) assessment. This technology removes the need for pressure wires and adenosine used in traditional FFR assessments of the coronary arteries.

An example of the Medis QCA angiography imaging derived fractional flow reserve (FFR) assessment. This technology removes the need for pressure wires and adenosine used in traditional FFR assessments of the coronary arteries.

News | Cath Lab | July 22, 2021
July 22, 2021 — Medis Medical Imaging is partnering with CORRIB Core Lab and Sinomed in randomized clinical trial of
ast End Medical announced it received U.S. Food and Drug Administration (FDA) clearance for the company's SafeCross Transseptal Radiofrequency (RF) Puncture and Steerable Balloon Introducer System. The 3-in-1 system, which includes a steerable introducer sheath with an ultra-visible positioning balloon and radiofrequency (RF) puncture dilator, aims to provide a predictable and safe solution for electrophysiology (EP) and structural heart interventions requiring left atrial access.
News | Cath Lab | July 14, 2021
July 13, 2021 — East End Medical announced it received U.S.
There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone. #SCAI21 #SCAI2021 Creating a card0-renal program.

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone.

Feature | Cath Lab | May 14, 2021 | By Dave Fornell, Editor
There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal fun
Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting proc

Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting procedures.

News | Cath Lab | May 12, 2021
May 12, 2021 — Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has
SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI heart attack. #SCAI21 #SCAI2021

SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI.

Feature | Cath Lab | May 06, 2021 | By Dave Fornell, Editor
April 29, 2021 — Here is the list of late-breaking study presentations and links to articles about each of them from
Most Stable Ischemic Heart Disease Patients Did Not Meet ISCHEMIA Trial Enrollment Criteria, raising questions about its application in real-world practice. #SCAI2021 Getty Images

Getty Images

News | Cath Lab | May 03, 2021
May 3, 2021 – Results from a new study find a broad range of patients who typically undergo revascularization for sta
New study demonstrates depression, HIV, mental health, obesity, alcohol and drug abuse are risk factors on most common type of heart disease in young black patients. Photo by Dave Fornell
News | Cath Lab | April 29, 2021
April 29, 2021 – A retrospective analysis of risk factors for coronary artery disease (CAD) in young African American
There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

News | Cath Lab | April 28, 2021
April 28, 2021 – Results from a retrospective observational study, presented today at...
A cardiac cath lab at Henry Ford Hospital in Detroit. Photo by Dave Fornell

A cardiac cath lab complex PCI case at Henry Ford Hospital in Detroit. Photo by Dave Fornell

News | Cath Lab | April 28, 2021